BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28

• Press Releases

  Biohope Announces Collaboration to Advance Immunobiogram for Renal Transplant

  November 4, 2025

   · 

  1 min read
• Press Releases

  BioInvent to Present Updated Phase 2a BI-1808 Monotherapy Data in CTCL at ASH 2025

  November 4, 2025

   · 

  5 min read
• Press Releases

  Wandercraft Gains Second FDA Indication Extension for Atalante X in Less Than Two Years, Extending Advanced Robotic Rehabilitation for More Patients with Severe Mobility Loss

  November 4, 2025

   · 

  6 min read
• Press Releases

  BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS

  November 4, 2025

   · 

  4 min read
• Press Releases

  Disc Medicine Announces Presentation of Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

  November 4, 2025

   · 

  5 min read
• Press Releases

  Tessera Therapeutics to Present New Preclinical Data From In Vivo Programs for Sickle Cell Disease and T Cell Therapies at the 67th American Society of Hematology Annual Meeting

  November 4, 2025

   · 

  2 min read
• Press Releases

  Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

  November 4, 2025

   · 

  4 min read
• Press Releases

  BioInvent to Present Early Phase 2a Data from Ongoing Trial with Triple Combination of BI-1206, Rituximab, and Calquence in r/r NHL, at ASH 2025

  November 4, 2025

   · 

  4 min read
• Press Releases

  March Biosciences Announces Oral Presentation of MB-105 Interim Phase 2 Clinical Data at American Society of Hematology Annual Meeting

  November 4, 2025

   · 

  3 min read
• Press Releases

  SELLAS Life Sciences Announces Presentation of Phase 2 Data of SLS009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory AML with MDS-Related Changes (AML-MR) at the 2025 American Society of Hematology (ASH) Annual Meeting

  November 4, 2025

   · 

  4 min read